Related Experiment Video
Updated: Mar 22, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Novel targeted therapies in adrenocortical carcinoma
Bhavana Konda1, Lawrence S Kirschner
1aDivision of OncologybDivision of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, The Ohio State University Wexner Medical Center and James Cancer Hospital and Solove Research Institute, Columbus, Ohio, USA.
Purpose Of Review:
Adrenocortical carcinoma is a rare cancer, but one that carries a poor prognosis due to its aggressive nature and unresponsiveness to conventional chemotherapeutic strategies. Over the past 12 years, there has been renewed interest in developing new therapies for this cancer, including identifying key signaling nodes responsible for cell proliferation.
Recent Findings:
Clinical trials of tyrosine kinase inhibitors as monotherapy have generally been disappointing, although the identification of exceptional responders may lead to the identification of targeted therapies that may produce responses in subsets of patients. Agents targeted to the Wnt signaling pathway, a known player in adrenal carcinogenesis, have been developed, although they have not yet been used specifically for adrenal cancer. There is current excitement about inhibitors of acetyl-coA cholesterol acetyl transferase 1, an enzyme required for intracellular cholesterol handling, although trials are still underway. Tools to target other proteins such as Steroidogenic Factor 1 and mechanistic target of rapamycin have been developed and are moving towards clinical application.
Summary:
Progress is being made in the fight against adrenocortical carcinoma with the identification of new therapeutic targets and new means by which to attack them. Continued improvement in the prognosis for patients with adrenal cancer is expected as this research continues.
Insights
New therapies targeting signaling pathways show promise for adrenocortical carcinoma, a rare cancer with poor prognosis. Research is identifying novel therapeutic targets to improve patient outcomes.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- Adrenocortical carcinoma (ACC) is an aggressive rare cancer with a poor prognosis.
- Conventional chemotherapy is often ineffective against ACC.
- Recent research focuses on identifying key signaling pathways driving ACC cell proliferation.
Purpose of the Study:
- To review recent advances in therapeutic strategies for adrenocortical carcinoma.
- To highlight novel molecular targets and emerging treatments for ACC.
- To discuss the potential impact of these advancements on patient prognosis.
Main Methods:
- Review of recent clinical trials and preclinical research in adrenocortical carcinoma.
- Analysis of targeted therapies including tyrosine kinase inhibitors and Wnt signaling pathway agents.
- Evaluation of emerging therapeutic targets such as acetyl-CoA cholesterol acyltransferase 1, Steroidogenic Factor 1, and mechanistic target of rapamycin.
Main Results:
- Tyrosine kinase inhibitors have shown limited success as monotherapy in ACC.
- Exceptional responders suggest potential for targeted therapies in specific patient subsets.
- Development of agents targeting Wnt pathway, acetyl-CoA cholesterol acyltransferase 1, Steroidogenic Factor 1, and mTOR are underway.
Conclusions:
- Significant progress is being made in identifying new therapeutic targets for ACC.
- Novel therapeutic approaches are being developed to combat this aggressive cancer.
- Continued research is expected to improve the prognosis for patients with adrenocortical carcinoma.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:27Tumor Immunotherapy
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:34Inhibition of Cdk Activity